Article Text

Download PDFPDF
Dose related growth response to indometacin in Gitelman syndrome
  1. Lynster C T Liaw,
  2. Kaushik Banerjee,
  3. Malcolm G Coulthard
  1. Department of Paediatric Nephrology, Royal Victoria Infirmary, Newcastle upon Tyne NE1 4LP, UK
  1. Dr Coulthard

Abstract

Growth failure is a recognised feature of Gitelman syndrome, although it is not as frequent as in Bartter syndrome. Indometacin is reported to improve growth in Bartter syndrome, but not in Gitelman syndrome, where magnesium supplements are recommended. This paper presents 3 sisters with Gitelman syndrome who could not tolerate magnesium supplements, and whose hypotension and polyuria were eliminated by taking 2 mg/kg/day indometacin, but who grew poorly. However, increasing the indometacin dose to 4 mg/kg/day improved their growth significantly, without changing their symptoms or biochemistry. Gastrointestinal haemorrhage necessitated the use of misoprostol.

  • Gitelman syndrome
  • Bartter syndrome
  • indometacin
  • height
  • growth

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • * ADC has adopted the Royal Pharmaceutical Society recommendation that journals use the recommended international non-proprietory name (rINN) for medicinal substances, following the recent European directive (92/27/EEC).